

# Andrew Silagy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4784889/publications.pdf>

Version: 2024-02-01

23  
papers

235  
citations

1040056

9  
h-index

1058476

14  
g-index

23  
all docs

23  
docs citations

23  
times ranked

394  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. <i>European Urology</i> , 2021, 79, 468-477.	1.9	35
2	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	7.0	30
3	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	3.1	28
4	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	5.4	20
5	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. <i>British Journal of Anaesthesia</i> , 2020, 125, e402-e404.	3.4	15
6	Immune checkpoint blockade in renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 739-750.	1.7	13
7	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	7.0	12
8	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	4.1	12
9	Identifying Clear Cell Renal Cell Carcinoma Coexpression Networks Associated with Opioid Signaling and Survival. <i>Cancer Research</i> , 2021, 81, 1101-1110.	0.9	10
10	Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. <i>European Urology Focus</i> , 2019, 5, 949-957.	3.1	9
11	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. <i>Urology</i> , 2020, 136, 169-175.	1.0	9
12	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 916-923.	1.6	8
13	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	9.4	7
14	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.	1.6	6
15	Preoperative nomogram predicting 12-year probability of metastatic renal cancer "evaluation in a contemporary cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 853.e1-853.e7.	1.6	6
16	Surgical innovation revisited: A historical narrative of the minimally invasive "Agarwal sliding" clip renorrhaphy technique for partial nephrectomy and its application to an Australian cohort. <i>BJU International</i> , 2021, 2, 211-218.	1.3	6
17	A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3359-3365.	2.2	3
18	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma "An exploratory analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 791.e17-791.e24.	1.6	3

#	ARTICLE	IF	CITATIONS
19	The association between modifiable perioperative parameters and renal function after nephrectomy. BJU International, 2022, 129, 380-386.	2.5	2
20	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.6	1
21	Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease. Canadian Urological Association Journal, 2020, 15, E103-E109.	0.6	0
22	Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).. Journal of Clinical Oncology, 2021, 39, 353-353.	1.6	0
23	Systemic immunological determinants of oncological outcomes after surgery for localized renal cell carcinoma. Clinical Genitourinary Cancer, 2022, , .	1.9	0